Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Jan 17;92(2):442–446. doi: 10.1073/pnas.92.2.442

Angiogenin antagonists prevent tumor growth in vivo.

K A Olson 1, J W Fett 1, T C French 1, M E Key 1, B L Vallee 1
PMCID: PMC42756  PMID: 7831307

Abstract

A noncytotoxic neutralizing monoclonal antibody (mAb), 26-2F, to human angiogenin (Ang), a potent inducer of neovascularization, has been reported to prevent or delay the establishment of HT-29 human tumor xenografts in athymic mice. In the present study the tumor model was modified to increase sensitivity to Ang antagonists to facilitate further investigations and comparisons of their capacity to inhibit tumor growth. An increase in the percentage of tumor-free mice from 10-25% to 65% is observed in this modified model after treatment with mAb 26-2F. An additional neutralizing mAb, 36u, that interacts with a different epitope on Ang similarly prevents the appearance of tumors, both alone and in combination with mAb 26-2F. In those tumors that develop in mice treated with these agents, the number of vascular elements is reduced. Actin, an Ang antagonist that unlike the mAbs binds both human and mouse Ang, also prevents the establishment of tumors while exhibiting no toxic effects at daily doses > 50 times the molar amount of circulating mouse Ang. Ang antagonists also inhibit the appearance of tumors derived from two other Ang-secreting human tumor cell lines--i.e., A549 lung adenocarcinoma and HT-1080 fibrosarcoma. These results demonstrate that inhibition of the action of Ang is an effective therapeutic approach for the treatment of malignant disease.

Full text

PDF
442

Images in this article

445Fig. 2
on p.445

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acharya K. R., Shapiro R., Allen S. C., Riordan J. F., Vallee B. L. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2915–2919. doi: 10.1073/pnas.91.8.2915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bicknell R., Vallee B. L. Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2. Proc Natl Acad Sci U S A. 1989 Mar;86(5):1573–1577. doi: 10.1073/pnas.86.5.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 1;1032(1):89–118. doi: 10.1016/0304-419x(90)90014-r. [DOI] [PubMed] [Google Scholar]
  4. Blood C. H., Zetter B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990 Jun 1;1032(1):89–118. doi: 10.1016/0304-419x(90)90014-r. [DOI] [PubMed] [Google Scholar]
  5. Boucher Y., Jain R. K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 1992 Sep 15;52(18):5110–5114. [PubMed] [Google Scholar]
  6. Dennis P. A., Rifkin D. B. Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. J Cell Physiol. 1990 Jul;144(1):84–98. doi: 10.1002/jcp.1041440112. [DOI] [PubMed] [Google Scholar]
  7. Fantini J., Rognoni J. B., Roccabianca M., Pommier G., Marvaldi J. Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colic adenocarcinoma cell clone HT29-D4. J Biol Chem. 1989 Jun 15;264(17):10282–10286. [PubMed] [Google Scholar]
  8. Fett J. W., Olson K. A., Rybak S. M. A monoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope. Biochemistry. 1994 May 10;33(18):5421–5427. doi: 10.1021/bi00184a010. [DOI] [PubMed] [Google Scholar]
  9. Fett J. W., Strydom D. J., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985 Sep 24;24(20):5480–5486. doi: 10.1021/bi00341a030. [DOI] [PubMed] [Google Scholar]
  10. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  11. Hallahan T. W., Shapiro R., Strydom D. J., Vallee B. L. Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin. Biochemistry. 1992 Sep 1;31(34):8022–8029. doi: 10.1021/bi00149a036. [DOI] [PubMed] [Google Scholar]
  12. Hallahan T. W., Shapiro R., Vallee B. L. Dual site model for the organogenic activity of angiogenin. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2222–2226. doi: 10.1073/pnas.88.6.2222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hobson B., Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer. 1984 Apr;49(4):405–413. doi: 10.1038/bjc.1984.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Horak E. R., Leek R., Klenk N., LeJeune S., Smith K., Stuart N., Greenall M., Stepniewska K., Harris A. L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992 Nov 7;340(8828):1120–1124. doi: 10.1016/0140-6736(92)93150-l. [DOI] [PubMed] [Google Scholar]
  15. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991 Nov 15;51(22):6180–6184. [PubMed] [Google Scholar]
  16. Hu G. F., Chang S. I., Riordan J. F., Vallee B. L. An angiogenin-binding protein from endothelial cells. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2227–2231. doi: 10.1073/pnas.88.6.2227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hu G. F., Strydom D. J., Fett J. W., Riordan J. F., Vallee B. L. Actin is a binding protein for angiogenin. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1217–1221. doi: 10.1073/pnas.90.4.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990 Dec 6;348(6301):555–557. doi: 10.1038/348555a0. [DOI] [PubMed] [Google Scholar]
  19. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975 Feb;5(2):112–117. doi: 10.1002/eji.1830050208. [DOI] [PubMed] [Google Scholar]
  20. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  21. Lobb R. R., Key M. E., Alderman E. M., Fett J. W. Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. Int J Cancer. 1985 Oct 15;36(4):473–478. doi: 10.1002/ijc.2910360410. [DOI] [PubMed] [Google Scholar]
  22. Maes P., Damart D., Rommens C., Montreuil J., Spik G., Tartar A. The complete amino acid sequence of bovine milk angiogenin. FEBS Lett. 1988 Dec 5;241(1-2):41–45. doi: 10.1016/0014-5793(88)81027-5. [DOI] [PubMed] [Google Scholar]
  23. Mahadevan V., Hart I. R. Metastasis and angiogenesis. Acta Oncol. 1990;29(1):97–103. doi: 10.3109/02841869009089997. [DOI] [PubMed] [Google Scholar]
  24. Moroianu J., Fett J. W., Riordan J. F., Vallee B. L. Actin is a surface component of calf pulmonary artery endothelial cells in culture. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3815–3819. doi: 10.1073/pnas.90.9.3815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Moroianu J., Riordan J. F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1677–1681. doi: 10.1073/pnas.91.5.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Olson K. A., French T. C., Vallee B. L., Fett J. W. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 1994 Sep 1;54(17):4576–4579. [PubMed] [Google Scholar]
  27. Polakowski I. J., Lewis M. K., Muthukkaruppan V. R., Erdman B., Kubai L., Auerbach R. A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice. Am J Pathol. 1993 Aug;143(2):507–517. [PMC free article] [PubMed] [Google Scholar]
  28. Rybak S. M., Auld D. S., St Clair D. K., Yao Q. Z., Fett J. W. C-terminal angiogenin peptides inhibit the biological and enzymatic activities of angiogenin. Biochem Biophys Res Commun. 1989 Jul 14;162(1):535–543. doi: 10.1016/0006-291x(89)92030-5. [DOI] [PubMed] [Google Scholar]
  29. Shapiro R., Riordan J. F., Vallee B. L. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986 Jun 17;25(12):3527–3532. doi: 10.1021/bi00360a008. [DOI] [PubMed] [Google Scholar]
  30. Shapiro R., Strydom D. J., Olson K. A., Vallee B. L. Isolation of angiogenin from normal human plasma. Biochemistry. 1987 Aug 11;26(16):5141–5146. doi: 10.1021/bi00390a037. [DOI] [PubMed] [Google Scholar]
  31. Shapiro R., Vallee B. L. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2238–2241. doi: 10.1073/pnas.84.8.2238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Shapiro R., Vallee B. L. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry. 1989 Sep 5;28(18):7401–7408. doi: 10.1021/bi00444a038. [DOI] [PubMed] [Google Scholar]
  33. Sharpe R. J., Byers H. R., Scott C. F., Bauer S. I., Maione T. E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst. 1990 May 16;82(10):848–853. doi: 10.1093/jnci/82.10.848. [DOI] [PubMed] [Google Scholar]
  34. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2232–2236. doi: 10.1073/pnas.89.6.2232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Soncin F., Shapiro R., Fett J. W. A cell-surface proteoglycan mediates human adenocarcinoma HT-29 cell adhesion to human angiogenin. J Biol Chem. 1994 Mar 25;269(12):8999–9005. [PubMed] [Google Scholar]
  36. Strydom D. J., Fett J. W., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Amino acid sequence of human tumor derived angiogenin. Biochemistry. 1985 Sep 24;24(20):5486–5494. doi: 10.1021/bi00341a031. [DOI] [PubMed] [Google Scholar]
  37. Waldmann T. A. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657–1662. doi: 10.1126/science.2047874. [DOI] [PubMed] [Google Scholar]
  38. Weidner N., Carroll P. R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993 Aug;143(2):401–409. [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES